Request Processed

Your registration request has been processed. We will contact you soon.

Register

PrevisionPolicy logo
  • Login
  • Register
  • About
  • Contact Us
1 2 3 4 5 6 Next › Last »

Prevision Policy Clips | FDA Hostages Would Be Held An Extra Week Under Short Term Continuing Resolution

December 14, 2022

Prevision Policy Clips | Merck/Moderna Phase III Trial Of Melanoma Cancer Vaccine Combined With Keytruda

December 13, 2022

Cytokinetics Omecamtiv Faces Tough Vote On Efficacy In Heart Failure – And “Yes” From Panel May Still Mean More Work Ahead On Dosing Strategy

December 12, 2022

Prevision Policy Clips | Isotretinoin iPledge REMS Modifications Will Be Advisory Committee Topic March 28-29

December 12, 2022

Prevision Policy Clips | ICER Is Not On CMS “Radar” For Price Negotiation Input At This Point

December 9, 2022

“Development Safety Update Report” (DSUR) Proposed By FDA To Replace IND Annual Report; “Comprehensive” Scope, Harmonized With EU Approach

December 8, 2022

Prevision Policy Clips | “Development Safety Update Report” (DSUR) Proposed Rule Released By FDA: Overhaul Of IND Safety Update

December 8, 2022

Prevision Policy Clips | IRA Implementation: CMS Will Kick Off Monthly Calls With Manufacturers December 13

December 7, 2022

Prevision Policy Clips | CBER Director Peter Marks To Address PDUFA VII Implementation, OTAT Reorg At The Biopharma Congress Feb. 13

December 6, 2022

FDA Rewrites Bioequivalence Statistical Guidance: New Version Includes More Options Than Current (2001) Final Guidance

December 5, 2022

Prevision Policy Clips | FDA Finalizes Checkpoint Inhibitor PK-Based Dosing Guidance

December 5, 2022

Prevision Policy Clips | FDA Updating Generic Drug Bioequivalence Statistical Guidance

December 2, 2022

Prevision Policy Clips | Ferring Rebyota Milestones: First FDA Approval For Microbiota-Based Live Biotherapeutic

December 1, 2022

COVID Lessons Learned: FDA Oncology Office Encouraging Use Of Remote Trials Post-Pandemic; Friends/ACSO Collecting “Proof Of Concept” Data

November 30, 2022

Prevision Policy Clips | Bluebird Sells Priority Review Voucher To Argenx For $102 Million

November 30, 2022

ICER Hemophilia Gene Therapy Reviews: FDA Labels Watched For Impact On Coverage; Uptake May Be Slowed By Patient Caution/Payer Controls

November 29, 2022

Prevision Policy Clips | Genentech Pulls Tecentriq Urothelial Carcinoma Indication, Following Through On Timeline

November 29, 2022

Advisory Committee Tracker: “Non-Inferiority” Will Be Theme Of Early 2023 Reviews Of Eylea Pediatric Trial And Cidara/Melinta Antifungal

November 28, 2022

FDA “Project FrontRunner” Case Study: Can Agency Move Multiple Myeloma Drug Development To Earlier Disease Stages?

November 28, 2022

Prevision Policy Clips | Sarepta DMD Gene Therapy BLA Gets Priority Review, May 29, 2023 Action Date

November 28, 2022

Prevision Policy Clips | A New Drug Pricing Milestone: $3.5 Million Per Dose Will Be List Price For Hemgenix

November 23, 2022

“Project FrontRunner” Is Oncology Center’s Push For Culture Change In Treating Earlier-Stage Disease With AA – And Guaranteeing Timely Confirmatory Studies

November 22, 2022

Prevision Policy Clips | GSK Will Withdraw Blenrep At FDA’s Request; Compassionate Use Will Be Available

November 22, 2022

Oncology Immunotherapy Resistance Is Key Area Of Interest For FDA, Cancer Researchers; National Cancer Policy Forum Workshop Focuses On Need For Early Proof-Of-Concept

November 21, 2022

Prevision Policy Clips | FDA Commissioner Seeking Senior Advisors On Chronic Disease And Mental Health

November 21, 2022
1 2 3 4 5 6 Next › Last »

Patient-Focused
Drug Development
Database

Access database reports on PFDD meetings.

Log In
LEARN MORE
PrevisionPolicy logo sailboat

What is Prevision Policy?

Prevision Policy provides breaking analysis for biopharma on drug regulation, policy and market access. Our continuous information service gives decision makers actionable insight when they need it most on FDA, CMS, Congress, and how developments in policy impact commercial success.

Prevision Policy was started with the belief that information must be trustworthy, interactive, fast as it is deep, and deliver the bottom line. Strategy is developed in real-time and the biopharma business landscape can change quickly and without warning. Our service has been developed to address those challenges and turn them into opportunities.

To request more information about a company license to the Prevision Policy continuous information service or to get further details about the services we offer, please click here.

Biopharma Congress

Tweets by PrevisionPolicy

Copyright © 2023 Prevision Policy. All Rights Reserved. Privacy Policy